Compile Data Set for Download or QSAR
maximum 50k data
Found 347 with Last Name = 'albrecht' and Initial = 'c'
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM50423721(CHEMBL595105)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141972(US8927534, 11)
Affinity DataIC50: >100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141975(US8927534, 20)
Affinity DataIC50: >100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141976(US8927534, 23)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141978(US8927534, 29)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141994(US8927534, 269)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141973(US8927534, 114 | US8927534, 83)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141981(US8927534, 120)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM50423736(CHEMBL591543)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141986(US8927534, 262)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141990(US8927534, 266)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-5(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141979(US8927534, 75)
Affinity DataIC50: <100nMpH: 9.6 T: 2°CAssay Description:Fibronectin was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates (Nalge Nu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C19(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50042590(CHEMBL3353863)
Affinity DataIC50:  630nMAssay Description:Inhibition of CYP2C19 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141975(US8927534, 20)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM50423721(CHEMBL595105)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141972(US8927534, 11)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141994(US8927534, 269)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141990(US8927534, 266)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141986(US8927534, 262)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM50423736(CHEMBL591543)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141976(US8927534, 23)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141978(US8927534, 29)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141979(US8927534, 75)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141973(US8927534, 114 | US8927534, 83)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-IIb(Homo sapiens (Human))
Shire Orphan Therapies

US Patent
LigandPNGBDBM141981(US8927534, 120)
Affinity DataIC50: >1.00E+3nMpH: 9.6 T: 2°CAssay Description:Fibrinogen was diluted with coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) and coated with 100 uL/well to Nunc-Immuno maxisorp plates over night...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C8(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50042591(CHEMBL3353862)
Affinity DataIC50:  2.40E+3nMAssay Description:Inhibition of CYP2C8 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C8(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50042590(CHEMBL3353863)
Affinity DataIC50:  3.10E+3nMAssay Description:Inhibition of CYP2C8 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C19(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50042700(CHEMBL3353881)
Affinity DataIC50:  4.00E+3nMAssay Description:Inhibition of CYP2C19 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50042700(CHEMBL3353881)
Affinity DataIC50:  1.70E+4nMAssay Description:Inhibition of CYP2C9 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2D6(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50042591(CHEMBL3353862)
Affinity DataIC50:  1.80E+4nMAssay Description:Inhibition of CYP2D6 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C8(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50042700(CHEMBL3353881)
Affinity DataIC50:  2.30E+4nMAssay Description:Inhibition of CYP2C8 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C19(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50042591(CHEMBL3353862)
Affinity DataIC50:  2.80E+4nMAssay Description:Inhibition of CYP2C19 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 3A4(Homo sapiens (Human))
Boehringer Ingelheim Pharmaceuticals Inc

Curated by ChEMBL
LigandPNGBDBM50341008(4-[2-(1,1-Dioxo-1lambda*6*-thiomorpholin-4-yl)-ace...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP3A4 using flourescent probe 7-benzyloxyquinoline and 7-benzyloxy-4-(trifluoromethyl)-coumarin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50341023(CHEMBL1762293 | N-(5-tert-butylisoxazol-3-yl)-4-(t...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP2C9 using flourescent probe 7-methoxy-4-trifluoromethylcoumarinMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2D6(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50341023(CHEMBL1762293 | N-(5-tert-butylisoxazol-3-yl)-4-(t...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP2D6 flourescent probe 3-[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarinMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 3A4(Homo sapiens (Human))
Boehringer Ingelheim Pharmaceuticals Inc

Curated by ChEMBL
LigandPNGBDBM50341023(CHEMBL1762293 | N-(5-tert-butylisoxazol-3-yl)-4-(t...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP3A4 using flourescent probe 7-benzyloxyquinoline and 7-benzyloxy-4-(trifluoromethyl)-coumarin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50341008(4-[2-(1,1-Dioxo-1lambda*6*-thiomorpholin-4-yl)-ace...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP2C9 using flourescent probe 7-methoxy-4-trifluoromethylcoumarinMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2D6(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50341008(4-[2-(1,1-Dioxo-1lambda*6*-thiomorpholin-4-yl)-ace...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP2D6 flourescent probe 3-[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarinMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 3A4(Homo sapiens (Human))
Boehringer Ingelheim Pharmaceuticals Inc

Curated by ChEMBL
LigandPNGBDBM50340991(4-(1,1-Dioxo-1lambda*6*-thiomorpholine-4-carbonyl)...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP3A4 using flourescent probe 7-benzyloxyquinoline and 7-benzyloxy-4-(trifluoromethyl)-coumarin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2D6(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50340991(4-(1,1-Dioxo-1lambda*6*-thiomorpholine-4-carbonyl)...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP2D6 flourescent probe 3-[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarinMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 3A4(Homo sapiens (Human))
Boehringer Ingelheim Pharmaceuticals Inc

Curated by ChEMBL
LigandPNGBDBM50042912(CHEMBL3354553)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of human CYP3A4More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50042912(CHEMBL3354553)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of human CYP2C9More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2D6(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50042912(CHEMBL3354553)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of human CYP2D6More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C19(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50042912(CHEMBL3354553)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of human CYP2C19More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50340991(4-(1,1-Dioxo-1lambda*6*-thiomorpholine-4-carbonyl)...)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of CYP2C9 using flourescent probe 7-methoxy-4-trifluoromethylcoumarinMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50042590(CHEMBL3353863)
Affinity DataIC50:  4.60E+4nMAssay Description:Inhibition of CYP2C9 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2D6(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50042590(CHEMBL3353863)
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2D6 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2D6(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50042700(CHEMBL3353881)
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2D6 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Boehringer Ingelheim Pharma

Curated by ChEMBL
LigandPNGBDBM50042591(CHEMBL3353862)
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2C9 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 3A4(Homo sapiens (Human))
Boehringer Ingelheim Pharmaceuticals Inc

Curated by ChEMBL
LigandPNGBDBM50042591(CHEMBL3353862)
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP3A4 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 347 total ) | Next | Last >>
Jump to: